Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Blood (2023) 142 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2023-185881

Published: 2023

Journal Articles

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Blood (2023) 142 (Supplement 1): 4646.

https://doi.org/10.1182/blood-2023-186182

Published: 2023

Journal Articles

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Blood (2023) 142 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2023-189300

Published: 2023

Journal Articles

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Blood (2023) 142 (Supplement 1): 6938.

https://doi.org/10.1182/blood-2023-178526

Published: 2023

Journal Articles

Role of Pegylated Liposomal Doxorubicin in Heavily Pretreated Relapsed Refractory Hodgkin Lymphoma Eligible for Autologous or Allogeneic Transplantation

Beatrice Casadei, Cinzia Pellegrini, Emanuele Sutto, Martina Cantelli, Lisa Argnani, Sabrina Zoli, Paolo Elia Coppola, Marianna Gentilini, Alice Morigi, Matteo Carella, Gabriele Gugliotta, Gianmarco Bagnato, Laura Nanni, Alessandro Broccoli, Vittorio Stefoni, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 6204.

https://doi.org/10.1182/blood-2023-178601

Published: 2023

Journal Articles

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Blood (2023) 142 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2023-184614

Published: 2023

Journal Articles

The Clinical Complexity of Langherans Cell Histiocytosis in Adult Patients: Experience of the Institute of Hematology of Bologna

Alessandro Broccoli, Gianmarco Bagnato, Lisa Argnani, Martina Cantelli, Beatrice Casadei, Cinzia Pellegrini, Sabrina Zoli, Emanuele Sutto, Paolo Elia Coppola, Marianna Gentilini, Alice Morigi, Matteo Carella, Gabriele Gugliotta, Laura Nanni, Vittorio Stefoni, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 6412.

https://doi.org/10.1182/blood-2023-178573

Published: 2023

Journal Articles

The Treatment of Burkitt Lymphoma with the Berlin-Frankfurt-Münster Protocol with Rituximab and Autologous Transplantation

Alessandro Broccoli, Gianmarco Bagnato, Lisa Argnani, Beatrice Casadei, Martina Cantelli, Cinzia Pellegrini, Sabrina Zoli, Emanuele Sutto, Paolo Elia Coppola, Marianna Gentilini, Alice Morigi, Matteo Carella, Gabriele Gugliotta, Laura Nanni, Vittorio Stefoni, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2023-178586

Published: 2023

Journal Articles

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Mark N Sorial, Min Jung Koh, Leora Boussi, Jessy Xinyi Han, Luke Peng, Ijeoma Julie Eche-Ugwu, Rui Duan, Matthew M. Lei, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven M. Horwitz, Maria J. Fernandez Turizo, Sean McCabe, Mwanasha Hamuza Merrill, Eric Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Hasmukh Jain, Manju Sengar, Thomas Eipe, Tanuja Shet, Shambhavi Singh, Uvette Lou, Hesham Raghib, Judith Gabler, Min Ji Koh, Carrie Van Der Weyden, Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie Ford, Martina Manni, Massimo Federico, Owen A. O'Connor, Maria Elena Cabrera, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2023) 142 (Supplement 1): 3080.

https://doi.org/10.1182/blood-2023-182341

Published: 2023

Journal Articles

Rituximab As an Effective Salvage Therapy in Pretreated Hairy Cell Leukemia Patients: The Bologna Experience

Alessandro Broccoli, Lisa Argnani, Laura Nanni, Gianmarco Bagnato, Matteo Carella, Beatrice Casadei, Paolo Elia Coppola, Gabriele Gugliotta, Ginevra Lolli, Marianna Gentilini, Alice Morigi, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 6526–6527.

https://doi.org/10.1182/blood-2022-158158

Published: 2022

Journal Articles

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Blood (2022) 140 (Supplement 1): 10976–10978.

https://doi.org/10.1182/blood-2022-162944

Published: 2022

Journal Articles

Critical Role of Hodgkin Lymphoma Cells-Derived Large and Small Extracellular Vesicles in the Regulation of the Immune-Inflammatory Microenvironment

Filippo Maltoni, Chiara Ciardiello, Laura Nanni, Martina Barone, Ghazal Narimanfar, Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Dorian Forte, Alfredo Budillon, Pier Luigi Zinzani, Lucia Catani

Blood (2022) 140 (Supplement 1): 11509–11511.

https://doi.org/10.1182/blood-2022-168706

Published: 2022

Journal Articles

Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem

Blood (2021) 138 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2021-154037

Published: 2021

Journal Articles

Gut Microbiota Role in Response to Checkpoint Inhibitor Treatment in Patients with Relapsed/Refractory B-Cell Hodgkin Lymphoma: The MICRO-Linf Study

Beatrice Casadei, Serafina Guadagnuolo, Monica Barone, Silvia Turroni, Lisa Argnani, Patrizia Brigidi, Pier Luigi Zinzani

Blood (2021) 138 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2021-146813

Published: 2021

Journal Articles

The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna

Alessandro Broccoli, Carolina Terragna, Vittorio Stefoni, Cinzia Pellegrini, Beatrice Casadei, MD, Miriam Marangon, Alice Morigi, Laura Nanni, MD, Ginevra Lolli, Matteo Carella, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 4005.

https://doi.org/10.1182/blood-2019-122832

Published: 2019

Journal Articles

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Reid W Merryman, MD, Luca Castagna, MD, Paolo Corradini, MD, Vincent T. Ho, MD, David A. Bond, MD, Samantha Jaglowski, MDMPH, Michael A Spinner, Sally Arai, MD, Robert Lowsky, MD, Alex F. Herrera, MD, Anna Guidetti, MD, Geoffrey Shouse, DO, PhD, Didier Blaise, MD PhD, Jean Marc Schiano De Colella, MD, Talha Badar, MD, Mehdi Hamadani, MD, Stephen M Ansell, MD PhD, Yago Nieto, MD PhD, Chloe Spilleboudt, MD, Tatyana A. Feldman, MD, Lori Dahncke, BSN, Anurag K. Singh, MD, Joseph P. McGuirk, DO, Mohamad Mohty, MD PhD, Remy Dulery, MD, Aspasia Stamatoulas Bastard, Roch Houot, MD PhD, Guillaume Manson, MD, Marie-Pierre Moles, MD, Corentin Orvain, MD, Kamal Bouabdallah, MD, Matthew J. Frigault, MD, Yi-Bin Chen, Ryan C. Lynch, MD, Stephen D. Smith, MD, Uttam Rao, MD, Michael T Byrne, DO, Jason Romancik, MD, Jonathon B. Cohen, MDMS, Robin M. Joyce, MD, Maryam Rahimian, MD, Asad Bashey, MD PhD, Hatcher J. Ballard, BS, Jakub Svoboda, MD, Laura Giordano, Valter Torri, Beatrice Casadei, MD, Martina Sollini, MD, Chiara De Philippis, MD, Massimo Magagnoli, MD, Armando Santoro, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Carmelo Carlo-Stella, MD

Blood (2019) 134 (Supplement_1): 775.

https://doi.org/10.1182/blood-2019-125039

Published: 2019

Journal Articles

Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci in Models of Ptcl

Luigi Scotto, PhD, Cristina Kinahan, B.S., Beatrice Casadei, MD, Owen A. O'Connor, MD, PhD

Blood (2017) 130 (Supplement 1): 2743.

https://doi.org/10.1182/blood.V130.Suppl_1.2743.2743

Published: 2017

Journal Articles

The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting

Vittorio Stefoni, Beatrice Casadei, MD, Barbara Botto, Paolo Corradini, MD, Antonello Pinto, Alessandro Re, MD, Stefania Badiali, Lisa Argnani, Pier Luigi Zinzani, MD PhD

Blood (2017) 130 (Supplement 1): 4087.

https://doi.org/10.1182/blood.V130.Suppl_1.4087.4087

Published: 2017

Journal Articles

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Blood (2015) 126 (23): 3937.

https://doi.org/10.1182/blood.V126.23.3937.3937

Published: 2015

Journal Articles

Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma

Pier Luigi Zinzani, MD PhD, Letizia Gandolfi, Beatrice Casadei, Cinzia Pellegrini, Alessandro Broccoli, MD, Enrico Derenzini, MD, Federica Quirini, Lorenzo Tonialini, Michele Cavo, MD, Lisa Argnani, Vittorio Stefoni

Blood (2015) 126 (23): 2725.

https://doi.org/10.1182/blood.V126.23.2725.2725

Published: 2015

NARROW

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Role of Pegylated Liposomal Doxorubicin in Heavily Pretreated Relapsed Refractory Hodgkin Lymphoma Eligible for Autologous or Allogeneic Transplantation

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

The Clinical Complexity of Langherans Cell Histiocytosis in Adult Patients: Experience of the Institute of Hematology of Bologna

The Treatment of Burkitt Lymphoma with the Berlin-Frankfurt-Münster Protocol with Rituximab and Autologous Transplantation

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Rituximab As an Effective Salvage Therapy in Pretreated Hairy Cell Leukemia Patients: The Bologna Experience

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Critical Role of Hodgkin Lymphoma Cells-Derived Large and Small Extracellular Vesicles in the Regulation of the Immune-Inflammatory Microenvironment

Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem

Gut Microbiota Role in Response to Checkpoint Inhibitor Treatment in Patients with Relapsed/Refractory B-Cell Hodgkin Lymphoma: The MICRO-Linf Study

The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci in Models of Ptcl

The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only